



Outlook

NABP Announces 2025 Leadership Award Recipients

From NABP <news@nabp.pharmacy>**Date** Wed 4/16/2025 8:14 PM**To** Barron, Karin (DOH) <karin.barron@dc.gov>

CAUTION: This email originated from outside of the DC Government. Do not click on links or open attachments unless you recognize the sender and know that the content is safe. If you believe that this email is suspicious, please forward to phishing@dc.gov for additional analysis by OCTO Security Operations Center (SOC).



NABP WEEKLY

*Educational, Regulatory,
and Association News*



NABP Announces 2025 Leadership Award Recipients

NABP has announced the recipients of the 2025 NABP Leadership Awards. Each year, the Association presents awards to individuals who have worked with unwavering dedication to ensure NABP's continued service to the regulation of pharmacy practice and to the state boards of pharmacy in protecting public health.

This year's leaders include the following:

- Julie Spier, RPh, recipient of the 2025 Carmen A. Catizone Honorary President Award;
- Jeffrey J. Mesaros, PharmD, JD, RPh, recipient of the 2025 NABP President's Award;
- Nova Scotia College of Pharmacists, recipient of the 2025 Fred T. Mahaffey Award;
- Jenni Wai, MBA, RPh, recipient of the 2025 John F. Atkinson Service Award;
- Maryann Alexander, PhD, RN, FAAN, recipient of the 2025 Henry Cade Memorial Award; and
- Caroline D. Juran, BSPHarm, DPh (Hon), recipient of the 2025 Lester E. Hosto Distinguished Service Award.

Meet the 2025 NABP Leadership Award Winners

Texas Takes Action Against Three Pharmacies for Violating State Board of Pharmacy Rules

Pursuant to Section 105 of the Drug Quality and Security Act (P.L. 113-54), Food and Drug Administration recently shared actions taken by the State of Texas against three local compounding pharmacies for operating in violation of the Texas State Board of Pharmacy Rules.

Their cases are described below:

- **Boudreaux's New Drug Store in Lake Charles, LA**, allegedly dispensed 3,650 prescriptions from September 11, 2020, to March 2, 2022, that were believed to be "sterile products compounded in the non-hazardous drug buffer room in a biological safety cabinet," which last passed its certification status in June 2020. The Louisiana Board of Pharmacy entered a Consent Order against the pharmacy, and the pharmacy was ordered to pay a \$25,000 fine.
- **Hallandale Pharmacy in Fort Lauderdale, FL**, operated without disclosing a disciplinary action issued by the Kentucky Board of Pharmacy on its application for licensure in Texas. The pharmacy allegedly dispensed, shipped, and sold 312 prescription drugs for a 23-month period to patients residing in Texas without having a Texas pharmacy license and shipped compounded medications to Mississippi patients without having a compounding certificate from the Mississippi Board of Pharmacy to engage in such practice there. The Texas Board ordered for the respondent's license to be reprimanded.
- **Sitlausdeo Pharmacy, LLC, in Houston, TX**, has failed to comply with the Remedial Plan #2020-06870. Additionally, the pharmacist-in-charge failed to follow the business of pharmacy within six months of the license being issued, did not complete an initial gloved fingertip/thumb sampling procedure prior to compounding sterile preparations, did not properly supervise pharmacy personnel, and neglected to report dispensing controlled substance prescriptions to the Texas Prescription Monitoring Program. The pharmacy personnel did not complete appropriate training prior to engaging in sterile compounding duties.

For more information on the Board orders, please contact the Texas State Board of Pharmacy.

Contact the Texas State Board of Pharmacy

NABP President Mesaros Highlights Goals for New Research and Innovation Institute

NABP has released a video from NABP President Jeffrey J. Mesaros, PharmD, JD, RPh, in which he discusses his presidential initiative addressing the rapid emergence and adoption of new technologies in the health care industry. To help boards of pharmacy and pharmacies navigate the regulatory scope of these technologies, Dr Mesaros is developing the Association's new Research and Innovation Institute. The Institute will provide an environment to share, study, and evaluate relevant technologies and digital health concepts and resources. It will also serve as an impartial connector and facilitator between the boards of pharmacy, regulated entities, and third parties so that new ideas and proof of concept projects can be tested in a neutral setting.

For more information about the presidential initiative, visit nabp.pharmacy/presidential-initiative.



Watch the Video

Innovations: '2024: A Year of Building Connections to Enhance Patient Care and Safety'

Throughout 2024, NABP continued to demonstrate the commitment it shares with its member boards to foster collaboration and drive innovation across the pharmacy regulatory landscape. The Association brings together member boards, pharmacists, and other organizations to share critical information, tackle evolving challenges, and prioritize patient safety. While this effort is most notable in the continued development of the NABP Research and Innovation Institute (see the [***September/October 2024 issue of Innovations®***](#) for details), NABP also maintained its efforts to increase educational resources, explore methods of alleviating burdens on regulators and pharmacists alike, and provide more options to the state boards of pharmacy in evaluating licensure candidate competency.

Catch the Full Cover Story

Amid Measles Outbreak, US Poison Centers Report Rise in Pediatric Vitamin A Exposure

United States poison centers are warning about an increase in vitamin A exposure cases in children, amid recent reports suggesting that some people are taking vitamin A or cod liver oil to prevent measles infection. According to America's Poison Centers, 86 cases of vitamin A exposure in children were reported between January 1 and March 31, 2025, which is a 38.7% increase in the number of cases compared to the same time last year. The organization recommends that patients receive the measles, mumps, and rubella vaccine to prevent measles infection and talk to their health care providers before taking vitamin A or other supplements.

[Read the Article](#)

WHO's New Guidance Empowers Countries to Improve Mental Health Care

A new guidance on improving mental health services to meet the international human rights standards, along with the latest evidence, has been released by [World Health Organization \(WHO\)](#). Developed with help from global experts, policymakers, and people who have lived with mental health conditions, the resource outlines policy directives, strategies, and reforms to promote and protect mental health systems. WHO's guidance stresses the social and structural determinants of poverty, housing, education, and employment on mental health.

[Download WHO's Guidance](#)

LAPPA Publishes New Report on Syringe Services Programs

The Legislative Analysis and Public Policy Association (LAPPA) has published a comprehensive report of the status of syringe services programs throughout the US and its territories. In addition to providing new, unused injection drug use supplies, syringe services programs collaborate with other organizations to provide substance use disorder treatment, naloxone and other overdose prevention tools, and more.

[Download the Summary of State Laws >](#)

NABP Weekly is a publication prepared by NABP. Please send any comments, questions, or suggestions about the electronic newsletter to commdept@nabp.pharmacy. We look forward to receiving your feedback.



Outlook

Two New Boards of Pharmacy Recognized as Wellbeing First Champions

From NABP <news@nabp.pharmacy>**Date** Wed 4/23/2025 7:36 PM**To** Barron, Karin (DOH) <karin.barron@dc.gov>

CAUTION: This email originated from outside of the DC Government. Do not click on links or open attachments unless you recognize the sender and know that the content is safe. If you believe that this email is suspicious, please forward to phishing@dc.gov for additional analysis by OCTO Security Operations Center (SOC).



NABP WEEKLY

*Educational, Regulatory,
and Association News*



Kansas and Ohio Boards of Pharmacy Recognized as Wellbeing First Champions

The Kansas State Board of Pharmacy and the Ohio Board of Pharmacy were awarded Wellbeing First Champion badges by the Dr. Lorna Breen Heroes' Foundation. As Wellbeing First Champions, these Boards verified that their credentialing applications do not include any intrusive mental health questions or stigmatizing language.

The Kansas and Ohio Boards are the latest **boards of pharmacy** to earn this recognition, following the Alaska Board of Pharmacy, Idaho Board of Pharmacy, and North Dakota Board of Pharmacy, which were awarded the badge earlier this year.

NABP supports the Wellbeing First Champion Challenge and other efforts to improve **pharmacists' mental health and well-being** and will continue to work with its member boards of pharmacy on this and other efforts that can help create a more resilient and healthier pharmacy workforce.

[Learn More About the Challenge](#)

Clozapine Manufacturers Send Guide and REMS Modification to FDA

Clozapine manufacturers have submitted a modification to [Food and Drug Administration \(FDA\)](#), per the agency's request, regarding the termination of the Clozapine Risk Evaluation and Mitigation Strategies (REMS) program and an update to the prescribing information for clozapine. Once FDA accepts the modification, the *newclozapinerems.com* website will be shut down. Additionally, the manufacturers have created a medication guide for patients. The guide and the modification to the Clozapine REMS program are expected to be approved by FDA in mid-June 2025.

The American Association of Psychiatric Pharmacists has shared steps from the clozapine manufacturers to help pharmacies prepare for the Clozapine REMS update and will inform pharmacy associations and other relevant organizations of any new information.

[Read More About the Clozapine REMS Program](#)

Prevent Drug Misuse: Dispose of Medications Properly During DEA's April Drug Take Back Day

Drug Enforcement Administration (DEA) is hosting its biannual [National Prescription Drug Take Back Day](#) on April 26, 2025, from 10 AM-2 PM. This event offers consumers an opportunity to safely dispose of their unneeded or expired medications at a collection site in their city. Last [October](#), 629,953 pounds (or 314 tons) of drugs were collected during DEA's Drug Take Back Day.

More than 10,000 year-round locations can be found using NABP's Drug Disposal Locator Tool available at [safe.pharmacy](#). By entering a zip code or address, consumers can find the nearest drug disposal sites on a map.

[Find a Drug Collection Site](#)

CDC Panel Discusses 2025-2026 Vaccine Guidance

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) met from April 15-16, 2025, to discuss vaccine recommendations for 2025-2026. ACIP's recommendations include the following:

- updating the Vaccines For Children resolution to include GSK's MenABCWY vaccine, and recommending its use when administering the MenACWY and MenB vaccines during the same visit;
- administering a single dose of the respiratory syncytial virus vaccine for adults ages 50-59 who are at risk of severe disease; and
- administering Bavarian Nordic's newly approved chikungunya vaccine for adults traveling to countries or territories exhibiting an outbreak.

CDC has not formally released the results of the panel.

[View the Details From the Meeting](#)

Counterfeit Ozempic Injection Detected in United States Supply Chain, FDA Warns

FDA is warning pharmacies not to use or sell Ozempic® injection 1 mg products with the labeled lot number PAR0362 and serial number beginning with 51746517, as they are counterfeit medications. This semaglutide injection was distributed outside of Novo Nordisk's authorized and secure supply chain. Even though FDA seized the illicit products on April 9, 2025, there is still concern that the products may be in the supply chain. The seized products are undergoing an investigation by FDA and Novo Nordisk for potential risks; the six adverse event reports that the agency received for this lot were not associated with these products.

[Read FDA's Warning](#)

Trump Administration Drug Policy Focuses on Treatment and Overdose Reduction

"Reduce the Number of Overdose Fatalities, with a Focus on Fentanyl" and "Provide Treatment That Leads to Long-Term Recovery" are among the six key areas that the White House Office of National Drug Control Policy will focus on during its first year. The *Statement of Drug Policy Priorities* outlines the office's plan to increase access to overdose prevention education and opioid overdose reversal medications, expanding treatment to medications for opioid use disorder and improving the integration of mental health treatment with clinical and recovery support services.

[View the Drug Policy Priorities](#)



April Is Pharmacists War on Diabetes Month

April has been designated as **Pharmacists War on Diabetes month**. This movement shines a light on the critical role pharmacists play in helping patients manage diabetes. CDC offers a toolkit for pharmacists interested in promoting the National Diabetes Prevention Program.

[Visit CDC's Web Page](#)
>



National Fentanyl Awareness Day Is April 29

National Fentanyl Awareness Day will be observed on April 29, 2025. DEA has created a toolkit listing various ways individuals can inform others about the dangers of illicit fentanyl and counterfeit prescription pills.

[Explore DEA's Toolkit](#)
>



#EndPolio This World Immunization Week: April 24-30

World Immunization Week will be held from April 24-30, 2025. This year's theme is "#EndPolio," which stresses the importance of ensuring that every child is vaccinated against this disease.

[Find Out More About the Observance](#)
>

NABP Weekly is a publication prepared by NABP. Please send any comments, questions, or suggestions about the electronic newsletter to **commdept@nabp.pharmacy**. We look forward to receiving your feedback.



National Association of Boards of Pharmacy®

[Unsubscribe](#)

This message was sent to **karin.barron@dc.gov** from **news@nabp.pharmacy**

NABP
National Association of Boards of Pharmacy
1600 Feehanville Dr
Mount Prospect, IL 60056